Transaction overview

Penfund, an independent provider of capital to North American middle-market companies, completed a $205 million unitranche loan on March 1, 2026, for DOCS Dermatology Group (DOCS), a dermatology practice headquartered in Cincinnati, Ohio. Founded in 1978, DOCS operates over 150 locations across twelve states and provides comprehensive medical, surgical, and cosmetic dermatology services.

Deal structure and financing

The transaction took the form of a leveraged buyout (LBO) funded entirely through debt via a $205 million unitranche loan. No equity investment was disclosed in the deal terms, suggesting that existing shareholders retained full ownership. Penfund led the financing as both advisor and lender, with SkyKnight Capital remaining as the primary equity sponsor of DOCS Dermatology Group. The exact leverage ratio and lock-up period for the acquired company were not provided, but unitranche structures typically offer a blend of senior and subordinated debt to create a single loan facility.

Strategic context

The rationale behind Penfund’s investment in DOCS lies in its strategic position within the healthcare sector, particularly dermatology. DOCS Dermatology Group is noted for its comprehensive service offerings across medical, surgical, and cosmetic dermatology. The unitranche financing allows DOCS to maintain financial flexibility while expanding operations under SkyKnight Capital's guidance. This transaction aligns with Penfund’s focus on supporting businesses in growth sectors through capital provision, emphasizing the importance of clinical excellence and patient-centered care.

Regulatory path

The $205 million LBO did not require significant regulatory scrutiny as it involved a private equity investment without public listing implications. The deal was likely reviewed by relevant U.S. authorities but did not necessitate any material remedies due to its non-public nature and limited market impact within the healthcare sector. Given that Penfund is based in Canada, there may have also been involvement from Canadian regulatory bodies, though specific details were not disclosed.